삼성에피스홀딩스

0126Z0KOSPI기타 금융업

47.0 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40

News Sentiment18.1 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 10.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Epis Holdings is a biotech investment holding company with two subsidiaries, Samsung Bioepis and Epis Nex Lab. Samsung Bioepis focuses on commercializing 11 biosimilar products, contributing 96.7% of 2025 revenue, and is expanding into ADC drug development. Epis Nex Lab, established in 2025, is focused on next-generation biotech platforms but has not yet generated revenue.

Number of Employees

18people

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER

110.69Industry Average 7.940.0Point

13.9x industry avg (risky)

PBR

1.60Industry Average 0.450.0Point

3.6x industry avg (risky)

ROE

—Industry Average 5.453.5Point

Debt Ratio

6.92Industry Average 16.996.5Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

32 totalPositive 21Neutral 10Negative 1Average Sentiment Score 72.2

Positive
삼성에피스, 서울바이오허브와 오픈이노베이션 참여 기업 2곳 선정
삼성에피스는 서울바이오허브와의 협력으로 프레이저테라퓨틱스와 바이온사이트를 선정하여 기술 혁신 및 사업화 지원을 강화함으로써 긍정적인 시장 반응을 이끌어냈다.
Positive
삼성바이오에피스, 인투셀과 ADC 1종 본계약 체결
삼성에피스홀딩스와 인투셀의 ADC 신약 후보물질 상업화 계약 체결로 인해 회사의 기술 및 사업 확장 기대감이 높아짐.
Neutral
제약·바이오 25곳, 5년간 산재 117건…정신질환 5건 중 2건은 사...
Industry-wide statistics on workplace accidents in pharmaceutical and biotech sectors over five years indicate 117 incidents, focusing on 끼임 (entanglement) accidents, but do not directly impact Samsung Epis Holdings specifically.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 380,000Won52-week high 743,00052-week low 335,500

1-month return1.0Point

1m -10.80% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (Nectin4 단백질 표적 고형암 치료제 후보물질 SBE303 연구개발 및 상업화 계약 체결)2026-07-22
Neutral결산실적공시예고(안내공시)2026-07-10
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (개량항체 공동기술개발 및 기술도입 옵션계약 체결)2026-07-09
Neutral최대주주등소유주식변동신고서2026-07-06
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (SB27(Keytruda 바이오시밀러) 제3상 임상시험 1차 유효성 분석 결과 발표)2026-06-29